中 | EN
Home
About
Products
R&D
Manufacturing
Partnering
News
IR
Sustainability
Join Us

News

Simcere Announces NMPA Acceptance of New Drug Application for Zemprocitinib in the Treatment of Rheumatoid Arthritis

November 6, 2026 — Simcere Pharmaceutical Group (02096) announced today that the New Drug Application (NDA) for zemprocitinib—an orally administered, ...

2026-11-06
Simcere Pharmaceutical Group and Lynk Pharmaceuticals Reach New Collaboration on Zemprocitinib for Dermatology Indications

On November 2, 2026, Simcere Pharmaceutical Group announced a further expansion of its commercialization collaboration with Lynk Pharmaceuticals (Zhej...

2026-11-02
12 Studies on Three Simcere Zaiming Innovative Medicines to Be Presented at ESMO 2026

The European Society for Medical Oncology (ESMO) 2026 congress will take place in Madrid, Spain, from October 23 to 27. Standing alongside ASCO and WC...

2026-10-21
Inmular Approved as First Domestically Developed Long Acting RSV Prophylactic Monoclonal Antibody in China

On September 3, 2026, Simcere Pharmaceutical Group Limited (02096) announced that Clulevibart Injection (brand name: Inmular®), a domestically...

2026-09-03
read more

6,500+

Staff

40+

Current Brands of Products

50+

Innovative Product Candidates

1,900+

Covering Class III Hospitals

17,000+

Covering Other Hospitals & Medical Institutions

Partnering

Therapeutic Areas

Telephone: 025-85566666

Address: 699-18 Xuanwu Avenue Nanjing China

Zipcode：210042

Fax：025-85471729

Terms of UsePrivacy Policy

Su ICP Bei No. 10205883 Su Gong Wang An Bei No. 32010202010345
Su ICP Bei No. 08104641-3 | (Su)–Non-business–2018-0092 (Internet Drug Information Service Qualification Certificate)
© Copyright 2026 Jiangsu Simcere Pharmaceutical Co., Ltd. 版权所有 All Rights Reserved.